Expression and correlation of CD44v6, vascular endothelial growth factor, matrix metalloproteinase-2, and matrix metalloproteinase-9 in Krukenberg tumor

World Journal of Gastroenterology

Volumn 11, Issue 32, 2005, Pages 5032-5036

  Lou, Ge ^a   Gao, Ying ^a   Ning, Xiao Ming ^a   Zhang, Qi Fan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

CD44v6; Krukenberg tumor; MMPs; VEGF

Indexed keywords

CD44V6 ANTIGEN; GELATINASE A; GELATINASE B; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; STATISTICAL SIGNIFICANCE; STOMACH CANCER;

EID: 24144470011     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i32.5032     Document Type: Article

References (46)

1. Zhao GH, Li TC, Shi LH, Xia YB, Lu LM, Huang WB, Sun HL, Zhang YS. Relationship between inactivation of p16 gene and gastric carcinoma. World J Gastroenterol 2003; 9: 905-909
2. Wang MW, Yang SB, Zhang ZQ, Zhu QF, Wang GS, Li H, Yao C, Wu BY, You WD. Gastroscopy follow-up study of premalignant gastric lesions in senile patients. Shijie Huaren Xiaohua Zazhi 2003; 11: 1279-1281
3. Shen B, Zhu JS. Study progress of providing with blood and intervene chemotherapy by arteries. Shijie Huaren Xiaohua Zazhi 2003; 11: 1425-1428
4. National gastric cancer pathology cooperation. Pathology study in 360 gastric cancer corpses examination. Chin J Pathol 1983; 12: 124-128
5. Gerber HP, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med 2003; 81: 20-31
6. Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Di Raimondo F, Dammacco F. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 2003; 88: 176-185
7. Conti CJ. Vascular endothelial growth factor: regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy. Oncologist 2002; 7(Suppl 3): 4-11
8. 44v6 protein expression in gastric carcinoma and precancerous lesions. Shijie Huaren Xiaohua Zazhi 2000; 8: 156-158
9. Junglin B, Menges M, Goebel R, Wittig BM, Weg-Remers S, Pistorius G, Schilling M, Bauer M, Konig J, Zeitz M, Stallmach A. Expression of CD44v6 has no prognostic value in patients with colorectal cancer. Z Gastroenterol 2002; 40: 229-233
10. Morrin M, Delaney PV. CD44v6 is not relevant in colorectal tumour progression. Int J Colorectal Dis 2002; 17: 30-36
11. Waas ET, Lomme RM, DeGroot J, Wobbes T, Hendriks T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer 2002; 86: 1876-1883
12. Kuittinen O, Soini Y, Turppeenniemi-Hujanen T. Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma. Eur J Haematol 2002; 69: 205-212
13. Jiang YS, Gao Y. Biologic characteristic of matrix metalloproteinase and its effects in soakage and metastasis of hepatic carcinoma. Shijie Huaren Xiaohua Zazhi 2000; 8: 1403-1404
14. Li J, Liu J, Lu HO, Jiang Y, Guo L, Li H. Immunohistochemistry analysis of CD44 aberrance type in ovarian cancer. Chin J Clini Oncol 1998; 25: 738-740
15. Wang J, Sui LH, Gao QY. Expression of transmembrane glycopreotein V6 and its signification in epithelia ovarian cancer. Chin J Clini Obs Gynecol 2001; 2: 16-18
16. Cai Q, Lu HF, Sun MH, Du X, Fan YZ, Shi DR. Expression of CD44 v3 and v6 proteins in human colorectal carcinoma and its relevance with prognosis. Shijie Huaren Xiaohua Zazhi 2000; 8: 1255-1258
17. 15, CD44v6 and nm23H1 mRNA with metastasis and prognosis of colon carcinoma. Shijie Huaren Xiaohua Zazhi 2000; 8: 887-891
18. Yamaguchi A, Goi T, Yu. J, Hirono Y, Ishida M, Iida A, Kimura T, Takeuchi K, Katayama K, Hirose K. Expression of CD44v6 in advanced gastric cancer and its relationship to hematogenous metastasis and longterm prognosis. J Surg Oncol 2002; 79: 230-235
19. Giavazzi R, Sennino B, Coltrini D, Garofalo A, Dossi R, Ronca R, Tosatti MP, Presta M. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol 2003; 162: 1913-1926
20. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002; 29(6 Suppl 16): 10-14
21. Bellamy WT. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol 2001; 28: 551-559
22. Taraboletti G, Poli M, Dossi R, Manenti L, Borsotti P, Faircloth GT, Broggini M, D'Incalci M, Ribatti D, Giavazzi R. Antiangiogenic activity of aplidine, a new agent of marine origin. Br J Cancer 2004; 90: 2418-2424
23. Gadducci A, Viacava P, Cosio S, Cecchetti D, Fanelli G, Fanucchi A, Teti G, Genazzani AR. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. Anticancer Res 2003; 23: 3001-3008
24. Ishikawa M, Kitayama J, Kazama S, Nagawa H. Expression of vascular endothelial growth factor C and D (VEGF-C and -D) is an important risk factor for lymphatic metastasis in undifferentiated early gastric carcinoma. Jpn J Clin Oncol 2003; 33: 21-27
25. Kakeji Y, Koga T, Sumiyoshi Y, Shibahara K, Oda S, Maehara Y, Sugimachi K. Clinical significance of vascular endothelial growth factor expression in gastric cancer. J Exp Clin Cancer Res 2002; 21: 125-129
26. 53 and outcome in patients with gastric carcinoma. Shijie Huaren Xiaohua Zazhi 2004; 12: 546-549
27. Zhang HT, Hu X. Relationship between VEGF and incursions and metastasis ingastric cancer. Shijie Huaren Xiaohua Zazhi 2003; 11: 344-345
28. 53 and VEGF in experimental gastric cancer in rats and the effect of decoction Weikang-ning. Shijie Huaren Xiaohua Zazhi 2003; 11: 997-1000
29. Mao ZB, Xiao MB, Huang JF, Ni HB, Ni RZ, Wei Q, Zhang H. Expression of VEGF and its signification in serum of gastric cancer. Shijie Huaren Xiaohua Zazhi 2002; 10: 1220-1221
30. Takahashi Y, Mai M. Significance of angiogenesis and clinical application of anti-angiogenesis. Nippon Geka Gakkai Zasshi 2001; 102: 381-384
31. Kitadai Y, Amioka T, Haruma K, Tanaka S, Yoshihara M, Sumii K, Matsutani N, Yasui W, Chayama K. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer 2001; 93: 662-666
32. Linderholm BK, Lindh B, Beckman L, Erlanson M, Edin K, Travelin B, Bergh J, Grankvist K, Henriksson R. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin Breast Cancer 2003; 4: 340-347
33. Liu F, Zhang YJ. Roles of VEGF-C and its receptor Flt-4 in proliferation and metastasis of primary breast cancer. Aizheng 2003; 22: 1053-1056
34. Yu CY, Pam KF, Xing DY, Liang G, Tan W, Zhang L, Lin D. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res 2002; 15: 6430-6433
35. Hao YD, Zhao YW, Kong LF, Zhang YP. Chang of MMP-2 enzymologic activity in tissues of human hepatocellular cancer. Shijie Huaren Xiaohua Zazhi 2000; 8: 952-953
36. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinase-2,-9 and tissue inhibitors of metalloproteinases-1,-2 in lung cancer-TIMP-1 as a prognostic marker. Anticancer Res 2000; 20: 1311-1316
37. Monig SP, Baldus SE, Hennecken JK, Spiecker DB, Grass G, Schneider PM, Thiele J, Dienes HP, Holscher AH. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2001; 39: 597-602
38. Kabashima A, Msehara Y, Kakeji Y, Baba H, Koga T, Sugimachi K. Clinicopathological features and overepression of matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis. Clin Cancer Res 2000; 6: 3581-3584
39. Kabashima A, Yan T, Sugimachi K, Tsuneyoshi M. Relationship between biologic behavior and phenotypic expression in intramucosal gastric carcinomas. Hum Pathol 2002; 33: 80-86
40. Cai H, Kong ZR, Chen HM. Matrix metalloproteinase-2 and angiogenesis in gastric cancer. Aizheng 2002; 21: 25-28
41. Hirvonen R, Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) in T (1-2) NO breast carcinoma. Breast Cancer Res Treat 2003; 7791: 85-91
42. Takahashi Y, Kitadai Y, Ellis LM, Bucana CD, Fidler IJ, Mai M. Multiparametric in situ mRNA hybridization analysis of gastric biopsies predicts lymph node metastasis in patients with gastric carcinoma. Jpn J Cancer Res 2002; 93: 1258-1265
43. Takahashi M, Oka N, Naroda T, Nishitani MA, Kanda K, Kanayama HO, Kagawa S. Prognostic significance of matrix metalloproteinases-2 activation ratio in renal cell carcinoma. Int J Urol 2002; 9: 531-538
44. Matsuyama Y, Takao S, Aikou T. Comparison of matrix metalloproteinase expression between primaru tumors with or without liver metastasis in pancreatic and colorectal carcinomas. J Surg Oncol 2002; 80: 105-110
45. Liang YY, Zhao T, He EST. Relationship between MMP-9, MMP-2 and metastasis of gastric cancer. Chin J General Surg 2000; 15: 119
46. Zhang CW, Zou SC, Xu WJ, Zhao CS. Expression of MMP-9 and its clinical signification. Zhongguo Weichang Waike Zazhi 2000; 3: 25-27